{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:54:56Z","timestamp":1793984096926,"version":"4.8.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Hidradenitis suppurativa (HS) is an inflammatory condition that remains challenging to manage. Deroofing is a surgical technique whereby the \u201cdermal roof\u201d of the entire lesion and sinus tracts are removed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>A prospective study was conducted to assess the efficacy and safety of deroofing in the management of both acute and chronic HS lesions in Hurley Stage I-III disease. The role of deroofing as an adjunct to adalimumab and the impact of deroofing on pain control and quality of life (QoL) were also quantified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Forty-four patients were enrolled in an open, single arm study treated by a single clinician. In total, 115 lesions were deroofed and patients were followed at 3 and 12 months after deroofing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>At 3 and 12 months, the recurrence rate was 10% (12\/115) and 11% (13\/108), respectively. Deroofing is an effective adjunctive treatment for patients on adalimumab. Deroofing also improved pain and QoL scores.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Deroofing is a safe and effective surgical technique that can be used for acute and chronic recurrent\/fixed lesions in Hurley I-III disease alone or as an adjunct to systemic therapies. Deroofing has a low recurrence rate, reduces pain, and improves QoL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004604","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T12:00:58Z","timestamp":1742212858000},"page":"e17-e21","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Surgical Deroofing in the Management of Hidradenitis Suppurativa Alone or as an Adjunct to Medical Therapies"],"prefix":"10.1097","volume":"51","author":[{"given":"Trang T.","family":"Vu","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Dermatology, University of Alberta, Edmonton, Alberta, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Soong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology, University of Alberta, Edmonton, Alberta, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reidar","family":"Hagtvedt","sequence":"additional","affiliation":[{"name":"Alberta School of Business, University of Alberta, Edmonton, Alberta, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Keeling","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology, University of Alberta, Edmonton, Alberta, Canada;"},{"name":"Symmetry Dermatology Laser & Esthetics, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"R1-20250630","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R2-20250630","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","article-title":"Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis","volume":"155","author":"Machado","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R3-20250630","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R4-20250630","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bjps.2016.05.029","article-title":"A systematic review of the use of lasers for the treatment of hidradenitis suppurativa","volume":"69","author":"John","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R5-20250630","first-page":"17","article-title":"Hidradenitis suppurativa: causes, features, and current treatments","volume":"11","author":"Vinkel","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"R6-20250630","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"R7-20250630","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/postgradmedj-2013-131994","article-title":"Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease","volume":"90","author":"Dufour","year":"2014","journal-title":"Postgrad Med J"},{"key":"R8-20250630","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R9-20250630","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R10-20250630","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/jdv.16023","article-title":"Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials","volume":"34","author":"Van der Zee","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R11-20250630","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000462979","article-title":"Medical and surgical treatment of hidradenitis suppurativa: a review","volume":"3","author":"Scuderi","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"R12-20250630","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/00325481.1959.11712723","article-title":"Treatment of chronic hidradenitis suppurativa: surgical modification","volume":"26","author":"Mullins","year":"1959","journal-title":"Postgrad Med"},{"key":"R13-20250630","first-page":"698","article-title":"Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa","volume":"17","author":"Dahmen","year":"2019","journal-title":"JDDG"},{"key":"R14-20250630","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaad.2009.12.018","article-title":"Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions","volume":"63","author":"Van der Zee","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R15-20250630","first-page":"360","article-title":"Ultrasound-guided de-roofing of epithelialized tunnels of hidradenitis suppurativa","volume":"62","author":"Sarkissian","year":"2021","journal-title":"Proced Dermatol"},{"key":"R16-20250630","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/pde.14955","article-title":"Surgical deroofing in pediatric patients with hidradenitis suppurativa","volume":"39","author":"Leszczynska","year":"2022","journal-title":"Ped Derm"},{"key":"R17-20250630","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s13555-020-00391-x","article-title":"Office-based surgical intervention for hidradenitis suppurativa (HS): a focused review for dermatologists","volume":"10","author":"Saylor","year":"2020","journal-title":"Dermatol Ther"},{"key":"R18-20250630","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"R20-20250630","doi-asserted-by":"crossref","first-page":"481.e1","DOI":"10.1016\/j.jaad.2010.01.033","article-title":"Commentary: unroofing for hidradenitis suppurativa, why and how","volume":"63","author":"Danby","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R21-20250630","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"R22-20250630","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"R23-20250630","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"key":"R24-20250630","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3 year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R25-20250630","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1468-3083.2011.04203.x","article-title":"Mild to moderate hidradenitis suppurativa treated with local excision and primary closure","volume":"26","author":"Van Rappard","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T20:00:31Z","timestamp":1751313631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004604","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}